The Drug Landscape
An overview of the entire drug landscape with a lens on disease, target, modality and more, along with a look at the regulatory announcements from H1.
The Trial and Commercial Landscapes
Analysis of the trial landscape by modality, phase and more, along with a look at the Deals and Companies data by deal type, company location and insight into the future of TPD.
About the report
The analysis includes:
-
- The Drug Landscape – An analysis of all 1850+ assets in the TPD database, including the 287 new assets added in H1 2024, along with a review of the regulatory announcements by drug and type
- The Trial Landscape and Future of TPD’s – An analysis of the 3150+ clinical trials tracked on Beacon TPD and a deeper look into the growth of novel modalities and how this affects the future of the space
- The Commercial Landscape – A look the commercial space by deal type, value and company data using our Deals and Companies database
You may also be interested in...
H1 2024 Oncolytic Viruses Landscape Review
H1 2024 Cancer Vaccine Landscape Review
The 2024 H1 TPD Landscape Review
Find out more
Beacon is the essential decision-support tool for developers of complex therapeutics. Our market-defining, proprietary ontologies, combined with the most accurate and comprehensive life sciences data, provide our customers with unparalleled visibility of the drug and trial landscape.
With Beacon, you can make drug development decisions with confidence. This is why 23 of the world’s top 25 drug developers trust us.
Speak with our team
Our dedicated account and research teams can help you with questions by showing you how this insight and data is collated on Beacon.
